C4 Therapeutics (CCCC) Competitors $2.54 -0.08 (-2.87%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. DAWN, PROK, DNTH, GHRS, MRVI, TBPH, UPXI, MGTX, ABUS, and KALVShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Day One Biopharmaceuticals (DAWN), ProKidney (PROK), Dianthus Therapeutics (DNTH), GH Research (GHRS), Maravai LifeSciences (MRVI), Theravance Biopharma (TBPH), Upexi (UPXI), MeiraGTx (MGTX), Arbutus Biopharma (ABUS), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Day One Biopharmaceuticals ProKidney Dianthus Therapeutics GH Research Maravai LifeSciences Theravance Biopharma Upexi MeiraGTx Arbutus Biopharma KalVista Pharmaceuticals C4 Therapeutics (NASDAQ:CCCC) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Do analysts recommend CCCC or DAWN? C4 Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 215.58%. Day One Biopharmaceuticals has a consensus target price of $25.29, indicating a potential upside of 263.04%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has higher valuation & earnings, CCCC or DAWN? Day One Biopharmaceuticals has higher revenue and earnings than C4 Therapeutics. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M5.07-$105.32M-$1.58-1.60Day One Biopharmaceuticals$131.16M5.44-$95.50M-$0.95-7.33 Does the media refer more to CCCC or DAWN? In the previous week, Day One Biopharmaceuticals had 12 more articles in the media than C4 Therapeutics. MarketBeat recorded 12 mentions for Day One Biopharmaceuticals and 0 mentions for C4 Therapeutics. Day One Biopharmaceuticals' average media sentiment score of 0.64 beat C4 Therapeutics' score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment C4 Therapeutics Neutral Day One Biopharmaceuticals Positive Which has more risk & volatility, CCCC or DAWN? C4 Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CCCC or DAWN? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is CCCC or DAWN more profitable? Day One Biopharmaceuticals has a net margin of -50.63% compared to C4 Therapeutics' net margin of -325.88%. Day One Biopharmaceuticals' return on equity of -19.01% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-325.88% -53.91% -33.26% Day One Biopharmaceuticals -50.63%-19.01%-16.99% SummaryDay One Biopharmaceuticals beats C4 Therapeutics on 14 of the 17 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.42M$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.6021.0030.8325.91Price / Sales5.07392.25469.77121.46Price / CashN/A43.2325.7828.79Price / Book0.839.739.466.03Net Income-$105.32M-$54.08M$3.27B$265.29M7 Day Performance-11.36%3.12%2.37%2.86%1 Month Performance12.17%4.57%3.88%1.23%1 Year Performance-61.82%10.22%30.52%19.11% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics1.4734 of 5 stars$2.54-2.9%$8.00+215.6%-60.7%$180.42M$35.58M-1.60150DAWNDay One Biopharmaceuticals2.2524 of 5 stars$6.81+0.9%$25.33+272.0%-48.9%$691.42M$131.16M-7.1760PROKProKidney3.7118 of 5 stars$2.54+7.6%$6.25+146.1%+0.8%$690.77M$80K-4.463DNTHDianthus Therapeutics1.161 of 5 stars$20.96+1.1%$53.00+152.9%-14.1%$667.59M$6.24M-6.4580News CoverageAnalyst RevisionHigh Trading VolumeGHRSGH Research1.4187 of 5 stars$12.67-0.9%$32.00+152.6%+13.9%$665.44MN/A-17.1210Positive NewsMRVIMaravai LifeSciences4.0292 of 5 stars$2.57-1.5%$5.75+123.7%-72.5%$664.66M$259.18M-1.89610Gap UpTBPHTheravance Biopharma2.0912 of 5 stars$13.61+3.5%$21.33+56.7%+71.9%$662.25M$64.38M56.71110High Trading VolumeUPXIUpexi2.611 of 5 stars$6.92-5.9%$15.50+124.0%+98.3%$656.81M$26M0.00130Positive NewsGap DownMGTXMeiraGTx4.4101 of 5 stars$7.97-2.4%$24.00+201.1%+87.8%$656.59M$33.28M-3.91300ABUSArbutus Biopharma2.6976 of 5 stars$3.38+0.3%$5.50+62.7%-7.7%$645.07M$6.17M-11.6690News CoveragePositive NewsKALVKalVista Pharmaceuticals4.0036 of 5 stars$13.34+3.6%$26.29+97.0%+6.2%$643.40MN/A-3.62100 Related Companies and Tools Related Companies Day One Biopharmaceuticals Competitors ProKidney Competitors Dianthus Therapeutics Competitors GH Research Competitors Maravai LifeSciences Competitors Theravance Biopharma Competitors Upexi Competitors MeiraGTx Competitors Arbutus Biopharma Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access